NMS · Financial Statements

Anavex Life Sciences Corp. (AVXL) Financial Statements

$1.27 NMS: AVXL Market Cap $118.19M

Anavex Life Sciences Corp. most recently reported annual revenue of $0, a net loss of $46.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Anavex Life Sciences Corp.: net profit was positive in 0 of 10 reported years; the most recent year shows a net loss of $46.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$0$0$0$0$0$0$0$0$0$0
Operating Expenses$0$0$0$0$31.0M$42.0M$51.0M$56.0M$53.0M$51.0M
Operating Profit$0$0$0$0$-31.0M$-42.0M$-51.0M$-56.0M$-53.0M$-51.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Other Income$0$2.0M$2.0M$3.0M$0$4.0M$3.0M$8.0M$10.0M$5.0M
Interest$0$0$0$0$0$0$0$1.0M$0$0
Depreciation$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-15.0M$-13.0M$-17.0M$-26.0M$-31.0M$-38.0M$-48.0M$-48.0M$-43.0M$-46.0M
Tax$-200,000$-440,000$-420,000$-310,000$14.2M$-710,000$-750,000$0$0$0
Net Profit$-15.0M$-13.0M$-17.0M$-26.0M$-26.0M$-38.0M$-48.0M$-48.0M$-43.0M$-46.0M
EPS$-0.42$-0.33$-0.39$-0.54$-0.45$-0.54$-0.62$-0.60$-0.52$-0.54
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$13.0M$11.0M$13.0M$15.0M$14.0M$14.0M$13.0M$14.0M$11.0M$7.0M$6.0M$7.0M
Operating Profit$-13.0M$-11.0M$-13.0M$-15.0M$-14.0M$-14.0M$-13.0M$-14.0M$-11.0M$-7.0M$-6.0M$-7.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-10.0M$-9.0M$-11.0M$-12.0M$-12.0M$-12.0M$-11.0M$-13.0M$-10.0M$-6.0M$-5.0M$-3.0M
Tax$630,000$0$0$0$1.1M$0$0$0$0$-320,000$500,000$-570,000
Net Profit$-10.0M$-9.0M$-11.0M$-12.0M$-12.0M$-12.0M$-11.0M$-13.0M$-10.0M$-6.0M$-5.0M$-3.0M
EPS$-0.13$-0.10$-0.13$-0.14$-0.14$-0.14$-0.13$-0.16$-0.11$-0.06$-0.06$-0.03

Over the 10 years reported for Anavex Life Sciences Corp., cash stood at $103.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 11.56 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$9.0M$28.0M$24.0M$25.0M$35.0M$162.0M$153.0M$154.0M$136.0M$104.0M
Current Assets$9.0M$28.0M$24.0M$25.0M$35.0M$162.0M$153.0M$154.0M$136.0M$104.0M
Cash$9.0M$27.0M$23.0M$22.0M$29.0M$152.0M$149.0M$151.0M$132.0M$103.0M
Inventory$0$0$0$-3.0M$0$0$0$0$0$0
Receivables$0$0$2.0M$3.0M$5.0M$9.0M$3.0M$3.0M$2.0M$1.0M
Fixed Assets$0$0$0$0$0$0$0$0$0$0
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$3.0M$4.0M$4.0M$5.0M$7.0M$11.0M$10.0M$13.0M$15.0M$9.0M
Current Liabilities$3.0M$4.0M$4.0M$5.0M$7.0M$11.0M$10.0M$13.0M$15.0M$9.0M
Borrowings$0$0$0$0$0$0$0$0$0$0
Other Liabilities$3.0M$4.0M$4.0M$5.0M$7.0M$11.0M$10.0M$13.0M$15.0M$9.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$6.0M$24.0M$20.0M$20.0M$27.0M$151.0M$142.0M$142.0M$120.0M$95.0M

For Anavex Life Sciences Corp., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $39.0M; free cash flow was positive in 0 of 10 years; financing activities used $3.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$-9.0M$-9.0M$-13.0M$-19.0M$-21.0M$-30.0M$-24.0M$-28.0M$-31.0M$-39.0M
Investing Cash Flow$0$0$0$0$0$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0$0$-1.0M$0$0$-3.0M
Net Cash Flow$-6.0M$18.0M$-5.0M$-1.0M$7.0M$123.0M$-3.0M$2.0M$-19.0M$-30.0M
Free Cash Flow$-9.0M$-9.0M$-13.0M$-19.0M$-21.0M$-30.0M$-24.0M$-28.0M$-31.0M$-39.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.08
EV / EBITDA-2.31
FCF Yield-20.00%
Quick Ratio15.62
Interest Coverage—
Return 1Y-79.39%
Return 3Y-68.47%
Return 5Y-88.30%

Anavex Life Sciences Corp. (AVXL) financials — frequently asked questions

What is Anavex Life Sciences Corp.'s annual revenue?

Anavex Life Sciences Corp. (AVXL) reported annual revenue of $0 in its most recent fiscal year.

What is Anavex Life Sciences Corp.'s net profit?

Anavex Life Sciences Corp. (AVXL) reported a net loss of $46.0M in its most recent fiscal year.

What is AVXL EV/EBITDA?

Anavex Life Sciences Corp.'s enterprise value to EBITDA (EV/EBITDA) ratio is -2.31. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
AVXL Overview AVXL Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.